Results 261 to 270 of about 177,994 (348)

Targeting PRMTs Creates Vulnerability of DNA Double‐Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC

Cancer Science, Volume 117, Issue 5, Page 1273-1285, May 2026.
Our work makes the proof of concept that there is a clinical benefit to target both PRMT1 and PRMT5 to maximize the anti‐tumoral effect of chemotherapy in triple negative breast cancer. ABSTRACT Patients with triple‐negative breast cancer (ER−, PR−, and HER2−) are routinely treated with chemotherapies that induce DNA damage.
Charlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, Louisane Eve, Rania El‐Botty, Laura Sourd, Elodie Montaudon, Ahmed Dahmani, Heloise Derrien, Stéphanie Sentis, Coralie Poulard, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer   +13 more
wiley   +1 more source

Hormone Therapy After Oophorectomy and Breast Cancer Risk in Women With BRCA Pathogenic Variant.

JAMA Netw Open
Regev-Sadeh S, Michaelson-Cohen R, Madorksy-Feldman D, Friedman E, Armon S, Qarawani A, Srebnik N, Haddad J, Eisenberg VH, Segev Y.   +9 more
europepmc   +1 more source

Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications. [PDF]

Int J Mol Sci
Anton SC, Nedelcu AH, Ianole V, Anton C, Danciu M, Morariu ID, Lupu A, Dascalescu G, Lupu VV, Knieling A, Nicolaiciuc D, Ciobica A, Chivasuta EA, Tirnovanu M, Dondiuc I, Ilea C, Grigore M, Anton E.   +17 more
europepmc   +1 more source

New partners for BRCA1 [PDF]

Nature Structural & Molecular Biology, 2007
openaire   +2 more sources

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, Volume 117, Issue 5, Page 1422-1433, May 2026.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer. [PDF]

NPJ Breast Cancer
Pasanisi J, Lamy C, Lecompte L, Vacher S, Schwartz M, Hamza A, Caputo SM, Ibadioune S, Courtois L, Berger F, Cockenpot V, Baulande S, Pierga JY, Callens C, Melaabi S, Colas C, Pasmant E, Kamal M, Dupain C, Servant N, Le Tourneau C, Bièche I.   +21 more
europepmc   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

Cancer Science, Volume 117, Issue 5, Page 1223-1234, May 2026.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa, Satoko Ugai, Atsushi Kondo, Kosuke Matsuda, Shu Kato, Genki Usui, Shiori Tanaka, Hwa‐Young Lee, Xinyuan Zhang, Hideo Miyagawa, Mai Chan Lau, Hiroshi Saeki, Yukihide Kanemitsu, Andrew T. Chan, Shuji Ogino, Minkyo Song, Juha P. Väyrynen, Tomotaka Ugai   +17 more
wiley   +1 more source

Risk of Radiation-Associated Contralateral Breast Cancer in Germline Mutation Carriers: A Meta-Analysis and Systematic Review. [PDF]

Cancers (Basel)
Prihharsanti CHN, Prajoko YW, Respati DRP, Tjandra KC, Mutmainnah F, Rismadha MB, Nugrahani ASD, Aryasatya DP, Manik AV, Nurkolis F, Limijadi EKS.   +10 more
europepmc   +1 more source

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy

Cancer Science, Volume 117, Issue 5, Page 1469-1480, May 2026.
Early screening for somatic alterations in localized prostate cancer could help predict biochemical recurrence risk and optimize salvage therapy selection. ABSTRACT The clinical significance of comprehensive genomic profiling (CGP) has been established in metastatic castration‐resistant prostate cancer (PC).
Kenji Zennami, Tetsuya Takimoto, Takuhisa Nukaya, Makoto Sumitomo, Mayu Takeda, Eiji Sugihara, Hideyuki Saya, Ryoichi Shiroki   +7 more
wiley   +1 more source

Commentary: With Regards to the WISDOM trial. [PDF]

BJC Rep
Narod SA.
europepmc   +1 more source